Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

Group 1 - Regenxbio reported a quarterly loss of $1.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.13, and compared to a loss of $1.05 per share a year ago, indicating a significant earnings surprise of -22.12% [1] - The company posted revenues of $21.36 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 21.16%, and this represents a decline from year-ago revenues of $22.3 million [2] - Over the last four quarters, Regenxbio has surpassed consensus EPS estimates only once, indicating challenges in meeting market expectations [2] Group 2 - The stock has gained approximately 6.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $102.44 million, while for the current fiscal year, it is -$0.56 on revenues of $293.35 million [7] Group 3 - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 41% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The current estimate revisions trend for Regenxbio is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]